SLC5A2 and type 2 diabetes mellitus: This study aimed to evaluate the association between sodium-glucose cotransporter-2 inhibitors (SGLT2i) use andBD risk in T2DM patients, compared with sulfonylureas.<h4>Methods</h4>We conducted a multi-center retrospective cohort study using electronic health records from Nanjing Medical University (January 2017-September 2022).